Kronos Bio

We’re looking forward to attending the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 31st – June 4th where we will present updated study data from KB-0742-1001 for our CDK9 inhibitor KB-0742, in a poster session on June 1st.     #ASCO #oncology    Link to Press Release: https://bit.ly/3JydjE1  

Today at the AACR Annual Meeting in San Diego, our poster #7550, “KB-0742, an Oral Highly Selective CDK9 Inhibitor, Demonstrates Preclinical Activity in Transcription Factor Fusion Driven Adenoid Cystic Carcinoma Patient-Derived Models” will be presented from 9:00 a.m. – 12:30 p.m.     Link to poster: https://bit.ly/3J9VIlM   #AACR #Oncology 

Today at the AACR Annual Meeting in San Diego, we presented two posters from our KB-0742 (CKD9 inhibitor) and p300 KAT inhibitor programs.     The first poster #1691, “p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma” was presented during the 9:00 a.m. - 12:30 p.m. poster session. Link to poster: https://bit.ly/49yCvVs    The second poster #CT158, “A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in relapsed refractory and transcriptionally addicted solid tumors” is being presented during the 1:30 p.m. - 5:00 p.m. poster session. Link to poster: https://bit.ly/4asEdsN    #AACR #oncology 

We’re looking forward to attending the AACR Annual Meeting in San Diego, CA from April 5-10, 2024, where will present three posters from our KB-0742 (CDK9 inhibitor) and p300 KAT inhibitor programs.     #AACR #Oncology 

Join Kronos Bio in honoring International Women's Day as we highlight our own breast cancer survivor Rocio Martin. #InternationalWomensDay #KronosBio #womeninscience

Yesterday our President and Chief Executive Officer Norbert Bischofberger, Ph.D., participated in a panel discussion on “Novel Oncology Targets” at the 44th Annual Cowen Health Care Conference. This forum provided a great opportunity for Norbert and other industry leaders to share their insights on the challenges and opportunities in drug discovery, recent innovations in the oncology space, as well as some key company updates. To check out the live audio webcast of the panel please visit the events and presentations section of the Kronos Bio website at www.kronosbio.com.

Today marks the first day of Myeloma Action Month. Multiple Myeloma is a cancer of bone marrow plasma cells, and it is the second most common blood cancer. Despite advancements in the treatment of Multiple Myeloma, there remains a significant unmet need for novel therapies. At Kronos Bio we are working diligently to progress our new development candidate, KB-9558, which targets the lysine acetyltransferase (KAT) domain of p300, a critical node of the Interferon regulatory factor 4 (IRF4) transcription regulatory network (TRN). IRF4 is a key driver in multiple myeloma. #MyelomaActionMonth

This week our team enjoyed a lunch and learn with Martin Larke, Senior Scientist, Computational Biology, about how we are using machine learning to understand cellular response to stress. This is an important topic in oncology research and one that is central to Kronos Bios’ development of therapeutics that target deregulated transcription. Thanks Martin for such an engaging session!

Members of the Kronos Bio team were busy this week at the 42nd annual J.P. Morgan Healthcare Conference in San Francisco. We shared our progress developing therapeutics that target deregulated transcription with investors and potential partners, including the latest on our first internally discovered molecule, KB-0742, a CDK9 inhibitor, as well as our new development candidate, KB-9558, a p300 KAT inhibitor. Thanks to everyone who met with us at #JPM. We appreciate your time, interest, and insights. 2024 is off to a good start! - with Norbert Bischofberger, Barbara Kosacz, Jorge DiMartino, Christopher Dinsmore, Charles Lin, Sarah Connors, and Margaux Bennett

Wishing you and your family health, happiness and success in 2024!